Boston Scientific’s next-gen DES
This article was originally published in The Gray Sheet
Executive Summary
Liberté coronary stent likely will be available in the U.S. by year-end, the company announces after receiving a CE mark for the bare-metal stent. Boston Scientific plans to begin U.S. trials of a paclitaxel-eluting stent on the Liberté platform in 2004...